Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SRX 246

Next Previous
X
Search
Drug Profile

SRX 246

Alternative Names: API 246; SRX246

Latest Information Update: 28 Jan 2022

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Azevan Pharmaceuticals
  • Class Anxiolytics; Behavioural disorder therapies; Heart failure therapies; Neuropsychotherapeutics; Small molecules
  • Mechanism of Action Vasopressin 1a receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Impulse control disorders; Post-traumatic stress disorders
  • Phase I/II Behavioural disorders
  • No development reported Anxiety disorders

Most Recent Events

  • 28 Jan 2022 No recent reports of development identified for phase-I development in Anxiety-disorders(In volunteers) in USA (PO, Capsule)
  • 18 Jun 2020 Azevan Pharmaceuticals suspends a phase II trial for Post-traumatic stress disorder in USA due to COVID-19 (PO) (NCT02733614)
  • 30 Jan 2020 SRX 246 is still in phase II trials for Post-traumatic stress disorder in USA (PO) (NCT02733614)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top